Suppliers / Emnar Pharma

Emnar Pharma

India Updated 9 July 2026

Emnar Pharma is an API manufacturer based in India. It holds 56 active US drug master files and 6 valid CEPs across a filed portfolio of 26 molecules. Its filings concentrate with CDSCO (India) and MINSA (CR). Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 28 August 2025 as VAI. Customs aggregates show $3.0M of exports covering 72 molecules to 22 destinations in 2025.

56
active US DMFs
6
valid CEPs
2
registered plants 1 with an FDA FEI number
2
filings across 2 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 28 August 2025 VAI US FDA
  • 6 June 2019 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Hyderabad, India Not on file
Anakapalli (District), India 3012336575

What they file, and where

Molecule Regulators Docs
Sodium Bicarbonate EDQM, US FDA 5
Empagliflozin US FDA 4
Lacosamide EDQM, US FDA 3
Levetiracetam EDQM, US FDA 3
Lithium Carbonate EDQM, US FDA 3
Potassium EDQM, US FDA 3
Tramadol EDQM, US FDA 3
Acotiamide US FDA 2
Apixaban US FDA 2
Bupropion US FDA 2
Show all 26 molecules on file
Calcium Carbonate US FDA 2
Capecitabine US FDA 2
Copper US FDA 2
Dapagliflozin US FDA 2
Dolutegravir US FDA 2
Gabapentin US FDA 2
Lamivudine US FDA 2
Linezolid US FDA 2
Magnesium US FDA 2
Pitolisant US FDA 2
Potassium Chloride US FDA 2
Potassium Sulfate US FDA 2
Pridinol US FDA 2
Tenofovir Disoproxil US FDA 2
Valproic Acid US FDA 2
Zonisamide US FDA 2

Also appears on these molecule pages

Capecitabine API Dolutegravir API Gabapentin API Lacosamide API Lamivudine API Levetiracetam API Tenofovir Disoproxil API Tramadol API Valproic Acid API Empagliflozin API Dapagliflozin API Apixaban API

Filings and GMP by regulator

Regulator Filings GMP certificates
CDSCO (India) 1 None
MINSA (CR) 1 None
US FDA None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $772K 8
2025 Not reported $3.0M 22
2024 Not reported $2.9M 27
2023 Not reported $91K 5

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Emnar Pharma comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 28 August 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts